Intestinal Lymphangiectasia

Back

Background

Intestinal lymphangiectasia is a rare protein-losing gastroenteropathy characterized by dilatation of the intestinal lymphatics and loss of lymph fluid into the gastrointestinal tract, leading to the development of hypoproteinemia, edema, lymphocytopenia, hypogammaglobinemia, and immunologic anomalies.[1]

Traditionally, protein-losing gastroenteropathies have been classified into three groups (depending on the mechanism of their etiology) that include the following[2] : (1) those causing mucosal damage leading to increased permeability to protein (usually not involving mucosal ulcerations), (2) those with mucosal erosions and/or ulcerations, and (3) those in which protein loss is secondary to mechanical lymphatic obstruction.

Although a more detailed discussion on protein-losing enteropathy is presented in another article, this article specifically addresses intestinal lymphangiectasia.

Pathophysiology

Intestinal lymphangiectasia is a rare, benign disease characterized by hypoproteinemia, edema, and lymphocytopenia, resulting from focal or diffuse dilatation of intestinal mucosal, submucosal, and subserosal lymphatics and loss of lymph fluid into the gastrointestinal (GI) tract.[3, 4] This leads to immunologic abnormalities, including hypogammaglobulinemia, anergy, and impaired allograft rejection. In addition to the loss of other serum components (eg, lipids), iron and certain trace metals may also be affected.[4]

Etiology

The following conditions can cause intestinal lymphangiectasia:

Epidemiology

United States data

The United States and international frequency of intestinal lymphangiectasia is unknown.

Race-, sex-, and age-related demographics

No racial predilection exists. However, there is a male-to-female ratio of 3:2.

Intestinal lymphangiectasia can be primary (ie, congenital), in which case it affects children and young adults (mean age of onset, 11 y). The diagnosis in these cases often occurs during the first decade of life, with the first manifestations being persistent diarrhea and peripheral edema. This condition can also be secondary to other disease states, thereby affecting older adults.[1, 5] In a series from Japan, the average age at onset was 22.9 years.

Prognosis

The clinical course of intestinal lymphangiectasia is highly variable with about 23% of patients showing improvement and 64% remaining unchanged; the mortality rate is 13%.

For patients with primary intestinal lymphangiectasia with an onset early in life (usually during the first decade), growth retardation usually occurs. The prognosis of patients with secondary intestinal lymphangiectasia depends on the extent and severity of the underlying disease.

Morbidity/mortality

Morbidity is related to the pathophysiology of this disease. Edema and diarrhea are predominant clinical features; however, the following negative sequelae are also observed:

Complications

Primary intestinal lymphangiectasia is associated with an increased risk of lymphoma.

Fibrotic entrapment of the small bowel is reported in patients with congenital intestinal lymphangiectasia.

Oral manifestations include gingivitis caused by poor lymphocytic function and enamel defects caused by poor calcium absorption.

History

Patients usually present in childhood with edema and nonbloody diarrhea. Edema may be unilateral or bilateral, depending on the site of the lesion. Edema in primary intestinal lymphangiectasia is usually bilateral, whereas the secondary type often manifests as unilateral edema and is caused by various neoplastic, infiltrative, and inflammatory lesions affecting one side of the body.

If the onset of disease occurs during the early part of the first decade of life, growth retardation usually ensues.

Frequently, steatorrhea, malabsorption, lymphocytopenia, and hypogammaglobulinemia are present.

Despite hypogammaglobulinemia, opportunistic infections rarely occur, although lymphocytopenia predisposes patients to abnormal cellular immunities, including homograft rejection and cutaneous anergy.

Ascites (often chylous ascites) and chylous pleural effusions are also reported in patients with long-standing lymphangiectasia.

Physical Examination

Primary intestinal lymphangiectasia

Peripheral edema is noted on physical examination in patients with primary intestinal lymphangiectasia.[6]

Macular edema on funduscopic examination has been reported and is a cause of reversible blindness.[7]

Pachydermoperiostosis has been associated with protein-losing enteropathy due to intestinal lymphangiectasia.[8] Pachydermoperiostosis is a rare hereditary disease characterized by clubbing of the fingers, periostosis, and skin changes.

Secondary lymphangiectasia

Secondary lymphangiectasia may involve multiple physical findings, depending on the etiology.

Laboratory Studies

Serum protein levels

The most common laboratory finding in intestinal lymphangiectasia is hypoproteinemia. Hypoalbuminemia is most prominent, and lymphocytopenia and hypogammaglobulinemia (eg, immunoglobulin A [IgA], immunoglobulin G [IgG], immunoglobulin M [IgM]) are also prominent. Cholesterol levels are not usually elevated.

Alpha1-antitrypsin levels

In random dry stools, levels of alpha1-antitrypsin has been used to indirectly measure protein leakage in the gastrointestinal (GI) tract. Alpha1-antitrypsin is negligibly broken down by intestinal proteases and, thus, is excreted intact in the stool. However, although measurement of stool alpha1-antitrypsin may serve as a good screening examination for protein loss, several studies have shown poor correlation between the value of alpha1-antitrypsin in the stool and its clearance measurement. In part, this is because of increased degradation of alpha1-antitrypsin in different milieus. For example, the breakdown of alpha1-antitrypsin is higher in environments where the pH level is less than 3, as in the stomach or small bowel in hyperacidity states.

The most specific test for protein loss in the GI tract is direct measurement of alpha1-antitrypsin clearance from plasma. Values greater than 24 mL/day in patients without diarrhea (diarrhea increases alpha1-antitrypsin clearance) and over 56 mL/day in those with diarrhea indicate protein loss in the GI tract. GI bleeding has also been shown to increase alpha1-antitrypsin clearance as a result of whole blood loss.

Imaging Studies

Double-contrast radiographs of the small bowel may be helpful, because they may show thickened folds due to intestinal edema from hypoproteinemia, nodular protrusions, and absence of mucosal ulcerations.

Ultrasonography and computed tomography (CT) scanning are also useful in identifying dilated intestinal loops, regular and diffuse thickening of the intestinal walls, plical hypertrophy, and mesenteric edema. CT scans may help show circumferential thickening of the small bowel wall with low attenuation (<30 H).

Multidetector CT (MDCT) scanning after direct lympangiography appears to provide an accurate evaluation and diagnosis of primary intestinal lymphangiectasia. In a retrospective study of 55 affected patients, all of whom underwent MDCT after direct lymphangiography, investigators noted that MDCT identified intra-intestinal, extra-intestinal, and lymphatic vessel abnormalities, including different degrees of intestinal dilatation, small bowel wall thickening, ascites, mesenteric edema, mesenteric nodules, lumbar trunk and intestinal trunk reflux.[9]

Procedures

Endoscopy

Repeatedly, the role of endoscopy has been proven useful. Small bowel enteroscopy not only helps detect mucosal changes suggestive of the disease but also allows acquisition of histologic samples to establish a diagnosis.[10, 11, 12]

White villi and/or spots (dilated lacteals), white nodules, and submucosal elevations are observed. Xanthomatous plaques are often visualized.

Capsule endoscopy

Capsule endoscopy has also been used to help identify the characteristic changes of intestinal lymphangiectasia not reachable with standard endoscopy.

Jejunal biopsy

Jejunal biopsy establishes a definitive diagnosis and shows dilation of mucosal and submucosal lymphatic channels. To increase the diagnostic yield, large biopsy forceps should be used when available. In addition, because of the patchy involvement of the small bowel, obtaining multiple biopsy samples from different areas is recommended.

Histologic Findings

Intestinal biopsy results reveal the characteristic dilatation of the lymph vessels of the mucosa and submucosa without any evidence for inflammation.



View Image

Intestinal villi of normal height with dilated lymphatics as usually seen on histology of villi in intestinal lymphagiectasia.

Medical Care

Treatment of patients with primary intestinal lymphangiectasia involves control of symptoms with the use of dietary, pharmaceutical, and behavioral modifications, such as the following:

Treatment of patients with secondary causes of intestinal lymphangiectasia involves management of the underlying disease.

Consultations

Whenever suspicion for protein-losing gastroenteropathy develops, refer the patient to a gastroenterologist.

Surgical Care

No role for surgery is evident for patients with primary intestinal lymphangiectasia; however, multiple causes of secondary intestinal lymphangiectasia can be addressed surgically, as follows:

Diet

Modify the patient's diet to reduce the intake of long-chain fatty acids, substituting short-chain and medium-chain fatty acids.[4] The rationale for this is based on the following two principles:

In a literature review, Desai et al investigated the efficacy of a medium-chain fatty acid diet in the treatment of primary intestinal lymphangiectasia in 27 patients compared to results of 28 control patients.[13] In the fatty acid group, complete symptom resolution occurred in 17 patients (63%), compared to 10 patients (35.7%) in the non-fatty acid group. In addition, there was 1 death (3.7%) in the fatty acid group, whereas the second group experienced 5 (17.8%) deaths. The authors concluded that a medium-chain fatty acid diet is a valid option for the treatment of pediatric patients.[13]

Theoretically, limiting the patient's salt intake could decrease edema, although no reports on this subject are known. In addition, the effects are probably not significant because diuretics do not have an important role in controlling edema in patients with primary intestinal lymphangiectasia.

Activity

No activity restrictions are suggested. Encourage patients to maintain an active lifestyle as much as their disease allows. However, adjustments must be made to minimize peripheral edema. For most patients, postural drainage by elevating the affected extremities above the level of the heart is easy to promote compliance. Suggestions to increase compliance may include the use of recliners in the evenings and the use of elastic support stockings to decrease the potential for cellulitis and lymphangitis.

Medication Summary

No maintenance medications for primary intestinal lymphangiectasia are indicated, other than the use of octreotide.

Patients with secondary intestinal lymphangiectasia should continue the maintenance medications of their primary underlying disease.

Two case reports documented the use of octreotide to control symptoms in refractory cases. In the first report, octreotide improved symptoms, findings on scintigraphy and endoscopy, and histology of the duodenum in a patient with intestinal lymphangiectasia.[19] The second report showed that octreotide at 200 mcg twice daily resulted in reduction in enteric protein loss from 16% to 4.1% in 5 days, and albumin infusions, which were necessary to maintain an acceptable level, were eliminated in a single patient with intestinal lymphangiectasia.[20]

Additional cases have been reported with the successful use of octreotide, including the long-acting formulation (LAR).[14, 21]

Octreotide (Sandostatin)

Clinical Context:  Acts in a similar fashion to the hormone somatostatin. Very potent inhibitor of growth hormone, glucagon, and insulin. Markedly decreases splanchnic blood flow and suppresses LH response to GnRH. Has a strong suppressive effect of GI hormones, including gastrin, motilin, secretin, and pancreatic polypeptide. Because of its suppressive effects on GI tract, octreotide is used in a variety of GI diseases, such as VIPoma and carcinoid tumors.

Class Summary

Used to inhibit effects of GI hormones.

Tranexamic acid (Cyklokapron)

Clinical Context:  Inhibits plasminogen activators, interfering with fibrinolysis.

Class Summary

Agents like tranexamic acid can competitively inhibit activation of plasminogen to plasmin, diminishing bleeding.

Author

Hisham Nazer, MBBCh, FRCP, DTM&H, Professor of Pediatrics, Consultant in Pediatric Gastroenterology, Hepatology and Clinical Nutrition, University of Jordan Faculty of Medicine, Jordan

Disclosure: Nothing to disclose.

Coauthor(s)

Dena Nazer, MD, FAAP, Assistant Professor of Pediatrics, Wayne State University School of Medicine; Chief, Child Protection Team, Children's Hospital of Michigan

Disclosure: Nothing to disclose.

Specialty Editors

Francisco Talavera, PharmD, PhD, Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Chief Editor

Burt Cagir, MD, FACS, Clinical Professor of Surgery, The Commonwealth Medical College; Director, General Surgery Residency Program, Robert Packer Hospital; Attending Surgeon, Robert Packer Hospital and Corning Hospital

Disclosure: Nothing to disclose.

Additional Contributors

Rajeev Vasudeva, MD, Clinical Professor of Medicine, Consultants in Gastroenterology, University of South Carolina School of Medicine

Disclosure: Received honoraria from Pricara for speaking and teaching; Received consulting fee from UCB for consulting.

Acknowledgements

Raoul Joubran, MD Fellow, Department of Internal Medicine, Division of Gastroenterology/Hepatology, University of Louisville School of Medicine

Disclosure: Nothing to disclose.

Anthony E Martin, MD Associate Professor of Medicine, Division of Gastroenterology, Hepatology, and Nutrition, Fellowship Training Program Director, University of Louisville School of Medicine

Anthony E Martin, MD is a member of the following medical societies: American Association for the Study of Liver Diseases, American College of Physicians, American Gastroenterological Association, American Society for Gastrointestinal Endoscopy, Association of Military Surgeons of the US, Kentucky Medical Association, and Special Operations Medical Association

Disclosure: Nothing to disclose. Richard Wright, MD Professor and Chief, Department of Medicine, Division of Gastroenterology/Hepatology, University of Louisville School of Medicine

Richard Wright, MD is a member of the following medical societies: American College of Physician Executives, American College of Physicians, American Gastroenterological Association, American Medical Association, and American Society for Gastrointestinal Endoscopy

Disclosure: Nothing to disclose.

References

  1. Alshikho MJ, Talas JM, Noureldine SI, et al. Intestinal lymphangiectasia: Insights on management and literature review. Am J Case Rep. 2016 Jul 21. 17:512-22. [View Abstract]
  2. Levitt DG, Levitt MD. Protein losing enteropathy: comprehensive review of the mechanistic association with clinical and subclinical disease states. Clin Exp Gastroenterol. 2017. 10:147-68. [View Abstract]
  3. Vignes S, Carcelain G. Increased surface receptor Fas (CD95) levels on CD4+ lymphocytes in patients with primary intestinal lymphangiectasia. Scand J Gastroenterol. 2009. 44(2):252-6. [View Abstract]
  4. Isa HM, Al-Arayedh GG, Mohamed AM. Intestinal lymphangiectasia in children. A favorable response to dietary modifications. Saudi Med J. 2016 Feb. 37(2):199-204. [View Abstract]
  5. Freeman HJ, Nimmo M. Intestinal lymphangiectasia in adults. World J Gastrointest Oncol. 2011 Feb 15. 3(2):19-23. [View Abstract]
  6. Wang X, Jin H, Wu W. Primary intestinal lymphangiectasia manifested as unusual edemas and effusions: A case report. Medicine (Baltimore). 2016 Mar. 95(10):e2849. [View Abstract]
  7. Lai Y, Yu T, Qiao XY, Zhao LN, Chen QK. Primary intestinal lymphangiectasia diagnosed by double-balloon enteroscopy and treated by medium-chain triglycerides: a case report. J Med Case Rep. 2013 Jan 14. 7(1):19. [View Abstract]
  8. Sethuraman G, Malhotra AK, Khaitan BK, et al. Familial pachydermoperiostosis in association with protein-losing enteropathy. Clin Exp Dermatol. 2006 Jul. 31(4):531-4. [View Abstract]
  9. Sun X, Shen W, Chen X, Wen T, Duan Y, Wang R. Primary intestinal lymphangiectasia: Multiple detector computed tomography findings after direct lymphangiography. J Med Imaging Radiat Oncol. 2017 Oct. 61(5):607-13. [View Abstract]
  10. Safatle-Ribeiro AV, Iriya K, Couto DS, et al. Secondary lymphangiectasia of the small bowel: utility of double balloon enteroscopy for diagnosis and management. Dig Dis. 2008. 26(4):383-6. [View Abstract]
  11. Takenaka H, Ohmiya N, Hirooka Y, et al. Endoscopic and imaging findings in protein-losing enteropathy. J Clin Gastroenterol. 2012 Aug. 46(7):575-80. [View Abstract]
  12. Oh TG, Chung JW, Kim HM, et al. Primary intestinal lymphangiectasia diagnosed by capsule endoscopy and double balloon enteroscopy. World J Gastrointest Endosc. 2011 Nov 16. 3(11):235-40. [View Abstract]
  13. Desai AP, Guvenc BH, Carachi R. Evidence for medium chain triglycerides in the treatment of primary intestinal lymphangiectasia. Eur J Pediatr Surg. 2009 Aug. 19(4):241-5. [View Abstract]
  14. Al Sinani S, Rawahi YA, Abdoon H. Octreotide in Hennekam syndrome-associated intestinal lymphangiectasia. World J Gastroenterol. 2012 Nov 21. 18(43):6333-7. [View Abstract]
  15. Troskot R, Jurcic D, Bilic A, Gomercic Palcic M, Tezak S, Brajkovic I. How to treat an extensive form of primary intestinal lymphangiectasia?. World J Gastroenterol. 2015 Jun 21. 21(23):7320-5. [View Abstract]
  16. Pollack SF, Geffrey AL, Thiele EA, Shah U. Primary intestinal lymphangiectasia treated with rapamycin in a child with tuberous sclerosis complex (TSC). Am J Med Genet A. 2015 Sep. 167A (9):2209-12. [View Abstract]
  17. Tan NBL, Tamblyn S, Hinds R. Primary intestinal lymphangiectasia as a first manifestation of tuberous sclerosis complex. J Pediatr Gastroenterol Nutr. 2017 Oct. 65(4):e96. [View Abstract]
  18. Kim NR, Lee SK, Suh YL. Primary intestinal lymphangiectasia successfully treated by segmental resections of small bowel. J Pediatr Surg. 2009 Oct. 44(10):e13-7. [View Abstract]
  19. Kuroiwa G, Takayama T, Sato Y, et al. Primary intestinal lymphangiectasia successfully treated with octreotide. J Gastroenterol. 2001 Feb. 36(2):129-32. [View Abstract]
  20. Ballinger AB, Farthing MJ. Octreotide in the treatment of intestinal lymphangiectasia. Eur J Gastroenterol Hepatol. 1998 Aug. 10(8):699-702. [View Abstract]
  21. Klingenberg RD, Homann N, Ludwig D. Type I intestinal lymphangiectasia treated successfully with slow-release octreotide. Dig Dis Sci. 2003 Aug. 48(8):1506-9. [View Abstract]
  22. Xinias I, Mavroudi A, Sapountzi E, et al. Primary intestinal lymphangiectasia: is it always bad? Two cases with different outcome. Case Rep Gastroenterol. 2013 Jan. 7(1):153-63. [View Abstract]
  23. Aoyagi K, Iida M, Yao T, Matsui T, Okada M, Fujishima M. Intestinal lymphangiectasia: value of double-contrast radiographic study. Clin Radiol. 1994 Nov. 49(11):814-9. [View Abstract]
  24. Aoyagi K, Iida M, Yao T, et al. Characteristic endoscopic features of intestinal lymphangiectasia: correlation with histological findings. Hepatogastroenterology. 1997 Jan-Feb. 44(13):133-8. [View Abstract]
  25. Bouhnik Y, Etienney I, Nemeth J, Thevenot T, Lavergne-Slove A, Matuchansky C. Very late onset small intestinal B cell lymphoma associated with primary intestinal lymphangiectasia and diffuse cutaneous warts. Gut. 2000 Aug. 47(2):296-300. [View Abstract]
  26. Filik L, Oguz P, Koksal A, Koklu S, Sahin B. A case with intestinal lymphangiectasia successfully treated with slow-release octreotide. Dig Liver Dis. 2004 Oct. 36(10):687-90. [View Abstract]
  27. Fuss IJ, Strober W, Cuccherini BA, et al. Intestinal lymphangiectasia, a disease characterized by selective loss of naive CD45RA+ lymphocytes into the gastrointestinal tract. Eur J Immunol. 1998 Dec. 28(12):4275-85. [View Abstract]
  28. MacLean JE, Cohen E, Weinstein M. Primary intestinal and thoracic lymphangiectasia: a response to antiplasmin therapy. Pediatrics. 2002 Jun. 109(6):1177-80. [View Abstract]
  29. Maconi G, Molteni P, Manzionna G, Parente F, Bianchi Porro G. Ultrasonographic features of long-standing primary intestinal lymphangiectasia. Eur J Ultrasound. 1998 Aug. 7(3):195-8. [View Abstract]
  30. Medical Economics Staff. Physicians' Desk Reference. 56th ed. Montvale, NJ: Medical Economics Co; 2001.
  31. Ralph PM, Troutman KC. The oral manifestations of intestinal lymphangiectasia: case report. Pediatr Dent. 1996 Nov-Dec. 18(7):461-4. [View Abstract]
  32. Rust C, Pratschke E, Hartl W, et al. Fibrotic entrapment of the small bowel in congenital intestinal lymphangiectasia. Am J Gastroenterol. 1998 Oct. 93(10):1980-3. [View Abstract]
  33. Salomons HA, Kramer P, Nikulasson S, Schroy PC. Endoscopic features of long-standing primary intestinal lymphangiectasia. Gastrointest Endosc. 1995 May. 41(5):516-8. [View Abstract]
  34. Sleisenger MV. Sleisenger and Fordtran's Gastrointestinal and Liver Disease: Pathophysiology, Diagnosis, and Management. 6th ed. Philadelphia: WB Saunders Co; 1998. 369-75.
  35. Takahashi H, Imai K. What are the objectives of treatment for intestinal lymphangiectasia?. J Gastroenterol. 2001 Feb. 36(2):137-8. [View Abstract]
  36. Yamada T, Alpers DH, Laine L, et al. Textbook of Gastroenterology: Self-Assessment Review. Philadelphia: Lippincott Williams & Wilkins; 1999.
  37. Yang DM, Jung DH. Localized intestinal lymphangiectasia: CT findings. AJR Am J Roentgenol. 2003 Jan. 180(1):213-4. [View Abstract]

Intestinal villi of normal height with dilated lymphatics as usually seen on histology of villi in intestinal lymphagiectasia.

Intestinal villi of normal height with dilated lymphatics as usually seen on histology of villi in intestinal lymphagiectasia.